CBLN1 and Parkinson disease: Importantly, elevated Cer levels modeled in genetic-based preclinical systems can be recapitulated in PD patients, in which plasma levels of certain sphingolipids are found to be altered (Mielke et al., 2013; Guedes et al., 2017).